Videos
Advertisement
Advertisement
Trending on Urology Times
1
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
2
ESMO On Location 2026 Day 1
3
Gedatolisib plus darolutamide shows preliminary activity in mCRPC
4
Michael Cookson, MD, reacts to Anktiva’s expanded approval in NMIBC
5